Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 4 · 57.1%Low 2 · 28.6%Moderate 1 · 14.3%High 0 · 0%

Peginterferon alpha‐2a vs peginterferon alpha‐2b

All‐cause mortality Deaths during and after the treatment · people with chronic hepatitis C

It is very uncertain whether peginterferon alpha‐2a changes all‐cause mortality Deaths during and after the treatment compared with peginterferon alpha‐2b (very low certainty).

1 finding from 1 review

Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C 2014 · Cochrane Headline outcomes only
RR 1.97 [0.64, 6.08]
1 study · 3070 participants
Very low

Peginterferon alpha‐2a vs peginterferon alpha‐2b

Liver morbidity · people with chronic hepatitis C

It is very uncertain whether peginterferon alpha‐2a changes liver‐related morbidity Number of events compared with peginterferon alpha‐2b (very low certainty).

1 finding from 1 review

Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C 2014 · Cochrane Headline outcomes only
RR 3 [0.7, 12.93]
1 study · 36 participants
Very low

Peginterferon alpha‐2a vs peginterferon alpha‐2b

Serious adverse events Number of events · people with chronic hepatitis C

Peginterferon alpha‐2a showed no clear difference in serious adverse events Number of events compared with peginterferon alpha‐2b (low certainty).

1 finding from 1 review

Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C 2014 · Cochrane Headline outcomes only
RR 1.12 [0.95, 1.3]
4 studies · 3900 participants
Low

Peginterferon alpha‐2a vs peginterferon alpha‐2b

Discontinuation of medication due to adverse events · people with chronic hepatitis C

Peginterferon alpha‐2a showed no clear difference in adverse events leading to treatment discontinuation Number of events compared with peginterferon alpha‐2b (low certainty).

1 finding from 1 review

Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C 2014 · Cochrane Headline outcomes only
RR 0.84 [0.57, 1.22]
12 studies · 5340 participants
Low

Peginterferon alpha‐2a vs peginterferon alpha‐2b

All other (non‐serious) adverse events · people with chronic hepatitis C

1 finding from 1 review

Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C 2014 · Cochrane Headline outcomes only
no estimate extracted
9 studies · 4981 participants
Very low

Peginterferon alpha‐2a vs peginterferon alpha‐2b

Quality of life SF 36 and CLDQ · people with chronic hepatitis C

1 finding from 1 review

Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 434 participants
Very low

Peginterferon alpha‐2a vs peginterferon alpha‐2b

Sustained virological response · people with chronic hepatitis C

Peginterferon alpha‐2a probably leads to higher sustained virological response Absence of viraemia 24 weeks after… compared with peginterferon alpha‐2b (moderate certainty).

1 finding from 1 review

Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C 2014 · Cochrane Headline outcomes only
RR 1.12 [1.06, 1.18]
12 studies · 5013 participants
Moderate